Education
About Us
Working with TipRanks
Follow Us
Akero Therapeutics Inc (AKRO)
NASDAQ:AKRO
Total Valuation
Akero Therapeutics has a market cap or net worth of $2.84B. The enterprise value is $1.26B.
Market Cap$2.84B
Enterprise Value$1.26B
Share Statistics
Akero Therapeutics has 79.62M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding79.62M
Owned by Insiders3.25%
Owned by Instutions37.76%
Financial Efficiency
Akero Therapeutics’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is -36.28%.
Return on Equity (ROE)-33.60%
Return on Assets (ROA)-30.52%
Return on Invested Capital (ROIC)-36.28%
Return on Capital Employed (ROCE)-36.31%
Revenue Per Employee$0
Profits Per Employee-$4,000,952.381
Employee Count63
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Akero Therapeutics is -7.41. Akero Therapeutics’s PEG ratio is -0.25.
PE Ratio-7.41
PS Ratio0.00
PB Ratio2.49
Price to Fair Value2.49
Price to FCF-8.12
Price to Operating Cash Flow-8.12
PEG Ratio-0.25
Income Statement
In the last 12 months, Akero Therapeutics had revenue of $0.00 and earned -$252.06M in profits. Earnings per share was -$3.75.
Revenue$0.00
Gross Profit-$2.00K
Operating Income-$285.42M
Pretax Income-$252.06M
Net Income-$252.06M
EBITDA-247.37M
Earnings Per Share (EPS)-3.75
Cash Flow
In the last 12 months, operating cash flow was -$230.11M and capital expenditures $0.00, giving a free cash flow of -$230.11M billion.
Operating Cash Flow-$230.11M
Free Cash Flow-$230.11M
Free Cash Flow per Share-$2.89
Dividends & Yields
Akero Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-12.32%
Earnings Yield-13.50%
Stock Price Statistics
Beta1.33
52-Week Price Change73.11%
50-Day Moving Average45.38
200-Day Moving Average32.85
Relative Strength Index (RSI)43.18
Average Volume (3m)1.18M
Important Dates
Akero Therapeutics upcoming earnings date is May 20, 2025, Before Open.
Last Earnings DateFeb 28, 2025
Next Earnings DateMay 20, 2025
Ex-Dividend Date―
Financial Position
Akero Therapeutics as a current ratio of 19.38, with Debt / Equity ratio of <0.01
Current Ratio19.38
Quick Ratio19.38
Debt to Market Cap<0.01
Net Debt to EBITDA1.19
Interest Coverage Ratio61.14
Taxes
In the past 12 months, Akero Therapeutics has paid -$42.27K in taxes.
Income Tax-$42.27K
Effective Tax Rate0.00%
Enterprise Valuation
Akero Therapeutics EV to EBITDA ratio is -5.35, with an EV/FCF ratio of -6.64.
EV to Sales0.00
EV to EBITDA-5.35
EV to Free Cash Flow-6.64
EV to Operating Cash Flow-6.64
Balance Sheet
Akero Therapeutics has $743.08M in cash and marketable securities with $36.46M in debt, giving a net cash position of -$706.62M billion.
Cash & Marketable Securities$743.08M
Total Debt$36.46M
Net Cash-$706.62M
Net Cash Per Share-$8.87
Tangible Book Value Per Share$11.17
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Akero Therapeutics is $74.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$74.00
Price Target Upside96.81%
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast
EPS Growth Forecast-31.37%